TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study

This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).

Study Overview

• Status: Completed
• Conditions: Hepatocellular Carcinoma Non-resectable
• Intervention / Treatment: Drug: TACE combined with sorafenib and tislelizumab

Detailed Description

This is a Phase II study to evaluate the efficacy and safety of TACE combined with sorafenib and tislelizumab in patients with advanced HCC.

30 subjects with advanced HCC (Barcelona-Clinic- Liver-Cancer [BCLC] stage C, or China liver cancer staging [CNLC] IIIa and IIIb) will be enrolled in the study.

Both sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated based on the evaluation of follow-up laboratory and imaging examination. Sorafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sorafenib administration will be delayed in cases of grade ≥2 hand-foot syndrome, grade >3 hematologic toxicities or grade ≥3 hypertension. After recovery, sorafenib will be reintroduced at a reduced dose according the sorafenib dose delay and reduction guidelines. Treatment of tislelizumab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510260
      • The Second Affiliated Hospital of Guangzhou Medical University
    • Guangzhou, Guangdong, China, 510260
      • The 2nd Affiliated Hospital of Guangzhou Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Advanced HCC (BCLC stage C, or CNLC IIIa and IIIb ) with diagnosis confirmed by histology/cytology or clinically
• Disease not amenable to curative therapies but amenable to TACE
• At least one measurable untreated lesion
• No prior systemic therapy for HCC
• Child-Pugh score 5-7
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
• Adequate organ and hematologic function
• Life expectancy of at least 3 months
• For women of childbearing potential and for men: agreement to remain abstinent

Exclusion Criteria:

• Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
• Diffuse HCC
• Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or upper mesenteric vein
• Inferior vena cava tumor thrombus
• Metastatic disease that involves major airways or blood vessels
• Symptomatic, untreated or progressing central nervous system metastasis
• Uncontrolled tumor-related pain
• Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC
• Treatment with systemic immunostimulatory agents
• Use of herbal therapies or traditional Chinese medicines with anti-cancer activity within 2 weeks
• History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
• Uncontrolled ascites, hydrothorax or pericardial effusion
• Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment
• Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring blood infusion, endoscopic or surgical intervention within 3 months
• Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding
• History of gastrointestinal (GI) perforation and/or fistula in the past 6 months history of GI obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection, complicated by chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea
• History of hepatic encephalopathy
• History of organ and stem cell transplantation
• Long-term daily treatment with a non-steroidal anti-inflammatory drug (NSAID)
• Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10 mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea symptoms such as asthma and chronic obstructive pulmonary disease is allowed
• History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
• Active tuberculosis
• Active severe infection; use of antibiotics within 2 weeks prior to injection of tislelizumab
• Autoimmune disease or immune deficiency
• Inadequately controlled hypertension; history of hypertensive crisis or hypertensive encephalopathy
• Bleeding diathesis or significant coagulopathy
• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks; non-recovery from side effects of these procedure
• History of venous thromboembolism in the past 6 months, but implantable IV ports or catheter-derived thrombosis, superficial venous thrombosis, or thrombosis after conventional anticoagulant therapy are excluded
• Current or recent use of aspirin or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol uncontrolled metabolic disorder, non-malignant organ or systemic disease or secondary carcinomatous reaction, with high medical risk and/or uncertainty of life expectancy evaluation
• Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study
• Female patients who are pregnancy or breastfeeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: TACE-Sor-Tis; TACE combined with sorafenib and tislelizumab.

Drug: TACE combined with sorafenib and tislelizumab; Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	The time from initiation of treatment until the date of death from any cause.	24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AEs)	Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.	24 months
Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST.	The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).	24 months
DCR assessed by investigators according to mRECIST.	The percentage of patients who had a tumor response rating of CR, PR, or SD.	24 months
Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).	The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.	24 months
Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST.	The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).	24 months
Duration of response (DOR) assessed by investigators according to RECIST 1.1 and irRECIST.	The time from the first occurrence of a documented objective response to disease progression (PD) or death.	24 months
PFS assessed by investigators according to Modified RECIST (mRECIST).	The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.	24 months
ORR assessed by investigators according to mRECIST.	The percentage of patients who had a best overall tumor response rating of CR or PR.	24 months
DOR assessed by investigators according to mRECIST.	The time from the first occurrence of a documented objective response to PD or death.	24 months

Collaborators and Investigators

• Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2020
• Primary Completion (Actual): October 11, 2022
• Study Completion (Actual): October 11, 2022

Study Registration Dates

• First Submitted: October 19, 2020
• First Submitted That Met QC Criteria: October 19, 2020
• First Posted (Actual): October 23, 2020

Study Record Updates

• Last Update Posted (Actual): October 13, 2022
• Last Update Submitted That Met QC Criteria: October 11, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Sorafenib
• Other Study ID Numbers: MIIR-03

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No